Aims: The aim of this study was to compare five-year clinical outcomes between an everolimus-eluting bioresorbable scaffold (BRS) and an everolimus-eluting metallic stent (EES) in STEMI patients.
Methods and results: This observational and retrospective study included 235 consecutive STEMI patients treated with BRS, compared with 235 STEMI patients treated with EES from the EXAMINATION trial, by applying propensity score matching. The primary endpoint was a device-oriented endpoint (DOCE), including cardiac death, target vessel myocardial infarction and target lesion revascularisation at five-year follow-up. Device thrombosis, according to the ARC criteria, was also evaluated. Optical coherence tomography (OCT) analysis was also performed at five years in event-free BRS patients. The cumulative incidence of five-year DOCE was higher in the BRS group as compared to the EES group (13.2% vs 7.6%, HR 1.87, 95% CI: 0.94-3.44, p=0.071), mainly driven by a higher rate of TLR (7.6% vs 1.7%, HR 1.15, 95% CI: 0.44-2.30, p=0.004). The five-year definite BRS thrombosis rate was also higher as compared to EES (4.2% vs 1.2%, HR 3.49, 95% CI: 0.95-12.82, p=0.054). OCT analysis showed a high incidence of neoatherosclerosis in the BRS group.
Conclusions: The five-year event risk was higher with BRS versus EES in STEMI. This suggests that the probability of obtaining favourable results at very long-term follow-up is low. Whether better results will be obtained with new-generation BVS remains to be determined.
Everolimus-eluting bioresorbable scaffolds (BRS) (Absorb™ bioresorbable vascular scaffold [BVS]; Abbott Vascular, Santa Clara, CA, USA) were designed to provide temporary mechanical support with antiproliferative responses to vascular injury similar to those of metallic drug-eluting stents but with complete resorption within several years, thereby restoring normal vascular function and potentially improving late outcomes1.
Analysis of data from four major randomised trials using poly-lactide-based BRS (Absorb BVS) have shown non-inferior outcomes to contemporary metallic drug-eluting stents in patients with stable coronary artery disease at short-term follow-up. However, they raised concerns about increased rates of target vessel-related myocardial infarction (TV-MI) and device thrombosis at long-term follow-up2,3. Of note, a number of BRS-related events in these trials were reported between one and three years –the period of active scaffold bioresorption4,5. Because of these concerns, the manufacturer withdrew the Absorb BVS from the market.
Nevertheless, other BRS with differing designs and drugs are still available on the market for use in clinical studies. One of these – a magnesium-based BRS – is currently being tested in ST-segment elevation myocardial infarction (STEMI), where their physiological advantages, such as late lumen enlargement and vasomotion, appear particularly appealing6,7. Previous studies on BRS in STEMI have shown contrasting results with either a non-inferior vascular healing response with a low rate of events or a higher rate of early device thrombosis at one-year follow-up8,9. However, all these studies are limited by short-term follow-up and lack of data beyond three years where the scaffold bioresorption may have a role in scaffold collapse with subsequent thrombosis10.
We therefore conducted a five-year follow-up of the BVS-EXAMINATION study, which matched consecutive STEMI patients receiving BRS with a cohort of STEMI patients receiving everolimus-eluting stents (EES) (XIENCE V®; Abbott Vascular) from the EXAMINATION randomised trial.
All consecutive STEMI patients already included in the one-year follow-up of the BVS-EXAMINATION study were included in this analysis8. The investigators at each institution who had already participated in the study were invited to perform a five-year follow-up of their STEMI patients treated with BRS who had already been included in the one-year study. If they agreed, they were then asked to complete a structured patient-level database with clinical outcome data, similar to the EXAMINATION database. Such individual patient data were sent to the study coordinator (S. Brugaletta), who was responsible for data consistency checking and for final pooling in a single database. All STEMI patients included in the BVS-EXAMINATION study were already matched with patients from the EXAMINATION randomised trial8. Five-year follow-up was performed in the EXAMINATION patients by clinical visits and in the BRS patients either by clinical visit or by telephone call.
Details about the primary PCI procedure, definition of clinical outcomes and optical coherence tomography (OCT) analysis are reported in Supplementary Appendix 1-Supplementary Appendix 3.
For the present analyses, individual data were pooled on a patient-level basis. Continuous variables are expressed as mean±SD and categorical variables are presented as absolute number and proportion (%). Details about propensity score matching analysis are reported in Supplementary Appendix 4.
Time-to-event variables are presented as Kaplan-Meier curves. Hazard ratios (HRs) of all events at 30 days, one year and five years were calculated using Cox proportional hazards models.
A two-sided p-value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS, Version 25.0 (IBM Corp., Armonk, NY, USA).
All but one of the participating institutions agreed to perform five-year clinical follow-up and to provide follow-up data. For these reasons, out of the 290 consecutive STEMI patients treated with BRS implantation originally included in the one-year follow-up of the BVS-EXAMINATION study, 235 patients were finally included for five-year follow-up. By applying the aforementioned methodology of propensity score matching, all of the 235 BVS patients were matched with 235 EES patients from the EXAMINATION trial, as previously shown8. The distribution of patient demographics and procedural characteristics between the two matched groups was similar to the one previously reported8 (Supplementary Table 1).
Five-year follow-up was available in 100% of EES patients and in 98% of BRS patients, as four patients were lost at follow-up (Figure 1).
Figure 1. Study flow chart.
CLINICAL OUTCOMES BETWEEN BRS AND EES
At five years, the device-oriented composite endpoint (DOCE) was numerically higher, but not statistically significant in the BRS as compared to the EES group (13.2% vs 7.6%; HR 1.87, 95% CI: 0.94-3.44, p=0.071) (Table 1). This difference was mainly driven by a higher rate of TV-MI (6.0% vs 2.5%, p=0.086) and target lesion revascularisation (TLR) (7.6% vs 1.7%, p=0.004) (Figure 2).
Figure 2. Kaplan-Meier curves. A) Kaplan-Meier event curves comparing BRS and EES for the composite device-oriented endpoint (DOCE) of cardiac death, target vessel myocardial infarction and target lesion revascularisation. B) Kaplan-Meier event curves comparing BRS and EES for cardiac death. C) Kaplan-Meier event curves comparing BRS and EES for target vessel myocardial infarction (TV-MI). D) Kaplan-Meier event curves comparing BRS and EES for target lesion revascularisation (TLR).
The definite device thrombosis rate was also higher in the BRS as compared to the EES group at five years (4.2% vs 1.2%, HR 3.49, 95% CI: 0.95-12.82, p=0.054) (Figure 3).
Figure 3. Kaplan-Meier event curves comparing BRS and EES for definite device thrombosis.
In a landmark analysis from one to five years, no differences were found between the BRS and EES groups in terms of DOCE (7.8% vs 4.3%, p=0.122) or cardiac death (6.0% vs 4.3%, p=0.574). A numerically higher rate of TV-MI (3.4% vs 1.7%, p=0.258) and definite device thrombosis (2.2% vs 0.9%, p=0.283) was found between one and five years in the BRS versus the EES group with a statistically significant higher incidence of TLR (5.2% vs 0.9%, p=0.006). No differences were found in terms of dual antiplatelet therapy between the BRS and EES groups at five years (3.4% vs 5.0%, p=0.647).
A total of 88 patients were screened to participate in the OCT study. A total of 48 patients were excluded (4 patients died, 5 patients had a TLR, 4 patients had a TV-MI, 15 patients because of severe comorbidities, 2 patients because of oral anticoagulation, 18 patients refused to participate). Out of the 40 patients who agreed to participate, one patient had target lesion occlusion and therefore 39 patients were eventually included in the analysis. Baseline clinical and angiographic characteristics are reported in Supplementary Table 2.
OCT data, as well as the combinations of lipid, calcification, and neovascularisation, as major atherosclerotic findings in this study, are shown in Table 2.
Overall, 31 patients (79%) exhibited at least one major finding of neoatherosclerosis. In particular, 8 (20%) patients had one major finding of atherosclerosis in the intima at five years. Two major findings were present in 9 (22%) patients and all three major findings of atherosclerosis were present in 13 (33%) patients (Figure 4).
Figure 4. Five-year OCT findings in STEMI patients treated with BRS. A) Lipid-laden intima (bidirectional white arc). B) Macrophage infiltration (white arrow). C) Deep calcium deposition (white arrow) >200 mm from the end-luminal border. D) Neointimal calcification (white arrow) <200 mm from the end-luminal border. E) Neovascularisation (white box). F) TCFA containing lipidic neointima. G) Intimal rupture (white arrow). H) Plaque rupture (white arrow) and empty cavity. OCT: optical coherence tomography; TCFA: thin-cap fibroatheroma
This is the first study comparing five-year long-term follow-up of BRS versus EES in STEMI patients. The main findings can be summarised as follows: 1) the five-year DOCE rate was higher in the BRS versus the EES group, mainly driven by a higher rate of TLR, which was especially concentrated between one and five years; 2) the rate of long-term definite device thrombosis was also higher in the BRS versus the EES group; 3) in event-free patients, the incidence of neoatherosclerosis was remarkably high.
After initial enthusiasm in relation to bioresorbable scaffolds, long-term data together with BRS use in more complex lesions have shown not only a lack of superiority but even inferiority in terms of hard clinical endpoints as compared to drug-eluting metallic stents13,14. For these reasons, the Absorb BVS has been withdrawn from the market and the use of other BRS has been restricted to clinical studies15.
Against this background, the usefulness of BRS in STEMI is still controversial. From the clinical point of view, previous STEMI studies on BRS have shown comparable angiographic and OCT performance to everolimus-eluting metallic stents without a clear inferiority of BRS versus EES, with only higher device thrombosis especially in the early phase and without data beyond three-year follow-up, when scaffold bioresorption is complete8,9. The TROFI II trial, which is the only randomised STEMI trial of BRS versus EES, showed low rates of DOCE and device thrombosis at three years, in line with the favourable vascular healing process observed at six months16,17.
The MAGSTEMI trial, which randomised STEMI patients to a magnesium-based BRS (Magmaris®; Biotronik, Bülach, Switzerland) versus a metallic drug-eluting stent (DES) (Orsiro; Biotronik), recently showed a higher one-year vasodilation of the treated coronary segment after intracoronary nitroglycerine administration with Magmaris versus Orsiro18.
In this five-year follow-up of the BVS-EXAMINATION trial, we found a higher rate of DOCE in the BRS versus the EES arm, mainly driven by a higher rate of TLR. The difference in terms of TLR between the groups became more important between one and five years. The incidence of device thrombosis was also higher in the BRS versus the EES group; this difference was already evident in the early phase and continued to increase up to five years. No differences were found between the groups in terms of dual antiplatelet therapy at five years, with a very low rate in both groups.
It is noteworthy that device-related clinical events continue to accrue yearly and that, whereas almost 90% of the five-year EES TLR were due to device thrombosis, only 55% of the BRS TLR were caused by device thrombosis. This means that different mechanisms may play a role in determining these events between metallic and bioresorbable devices. Mechanical causes, such as scaffold dismantling, and also neoatherosclerosis should be considered. Whereas scaffold dismantling is known to be important for device thrombosis, neoatherosclerosis may play a role either in thrombosis or in restenosis10,19 (Figure 5). In the case of metallic stents, neoatherosclerosis was known to contribute to the so-called late catch-up phenomenon. Although BRS were created to reduce this phenomenon, neoatherosclerosis following BRS implantation is not only qualitatively similar to that of DES, mainly composed of lipid, calcification and neovascularisation, but also seems to have a higher incidence19,20. Whereas in the RE-EXAMINATION study the incidence of neoatherosclerosis in STEMI patients who received EES was 22.6% at five years, in the present study we found, for example, a higher incidence (79%) in STEMI patients treated with BRS21. This high incidence confirms a previous observation in a group of stable angina patients enrolled in the ABSORB EXTEND study with OCT analysis at five years19. Data from other BRS platforms would be interesting in order to understand whether this phenomenon is related only to a specific BRS or if it is a class effect.
Figure 5. Examples of events caused by neoatherosclerosis following BRS implantation in STEMI. A) A case of BRS VLST at 1,550 days (4.25 years) after the index procedure. The main OCT finding related to the thrombosis was neoatherosclerosis with plaque rupture (white arrow and asterisk), visible also in the OCT longitudinal view. Near to the proximal and distal references, scaffold remnants were still observed. B) A case of scaffold restenosis due to neoatherosclerosis. A TCFA with cap rupture (white arrow and asterisk) was identified without thrombus. An FFR of 0.74 was measured. For both panels, in the longitudinal view the dotted lines correspond to the cross-section images. Minimum lumen area is shown per each cross-section. BRS: bioresorbable scaffold; FFR: fractional flow reserve; OCT: optical coherence tomography; TCFA: thin-cap fibroatheroma; VLST: very late scaffold thrombosis
Last but not least, a previous study suggested that, despite the increased risk of early events, BRS may still provide a theoretical net clinical benefit to patients in the very long term, but only if the risk of BRS failure beyond three years is substantially reduced as compared with EES22. However, our study shows that this event risk of BRS versus EES is maintained beyond four years, despite being performed in STEMI, a setting which is theoretically favourable to BRS17. Given this small degree of benefit that clinicians and decision makers may expect from the first-generation BRS at the current risk not only of device thrombosis but overall of target lesion failure, we guess that very long-term follow-up of the first-generation BRS has a very low probability of giving positive results. Whether different results will be obtained with new-generation BRS remains to be determined.
Several limitations of the study should be acknowledged. Due to the limited number of patients and events, and because the study was not randomised but based on a propensity score analysis, caution should be exercised in reaching firm conclusions. Dual antiplatelet therapy in STEMI patients with Absorb BVS implantation did not include guideline-oriented prasugrel or ticagrelor, and the duration was not according to the recommendations of the EAPCI Task Force. Of note, post-dilatation was performed in a relatively low number of patients. The nature of the clinical follow-up (clinical visit or phone call) differed in both clinical arms. Nevertheless, this study currently represents the largest cohort of STEMI patients treated with BRS compared with a control arm.
At five-year follow-up, STEMI patients treated with BRS showed a higher rate of DOCE compared with STEMI patients treated with EES, mainly driven by a higher rate of TLR, especially concentrated between one and five years. The incidence of BRS thrombosis was also higher as compared to EES. In event-free BRS patients, a high incidence of neoatherosclerosis, composed of lipid, including thin-cap fibroatheroma (TCFA), calcification and neovascularisation, was found at five years. Our five-year event risk of BRS versus EES suggests that the probability of obtaining positive results at very long-term follow-up is low. Whether better results will be obtained with new-generation BRS remains to be determined.
Impact on daily practice
This is the first study to investigate five-year outcomes in STEMI patients between BRS and best-in-class second-generation DES. STEMI patients treated with BRS have a higher incidence of DOCE, mainly driven by TLR clustered between one and five years. Device thrombosis is higher in BRS. OCT analysis also showed a high rate of neoatherosclerosis in BRS patients. This five-year event risk of BRS versus EES suggests a very low probability of positive results at very long-term follow-up. Effort should be concentrated on obtaining data from new-generation BRS.
Appendix. Study collaborators
Joan Antoni Gomez-Hospital, MD, PhD; Institute of Cardiology, Hospital of Bellvitge, Barcelona, Spain. Jose Hurtado, MD; Cardiology Department, Interventional Cardiology Unit, Virgen de la Arrixaca Hospital, Murcia, Spain. Mariano Valdés, MD; Cardiology Department, Interventional Cardiology Unit, Virgen de la Arrixaca Hospital, Murcia, Spain. Petr Widimsky, MD, DrSc; Cardiocenter, Third Faculty of Medicine, Charles University in Prague, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
This paper was guest edited by Alec Vahanian, MD, PhD; Department of Cardiology, Hôpital Bichat-Claude Bernard, and University Paris VII, Paris, France.
Conflict of interest statement
S. Brugaletta is a member of the advisory board of Boston Scientific and iVascular. T. Gori has received lecture fees from Abbott Vascular. V. Kocka has received personal fees from Abbott Vascular, Medtronic, B Braun, and Terumo. A. Cequier reports grants and personal fees from Abbott Vascular, Biosensors, Boston Scientific, and Medtronic, and grants from OrbusNeich, outside the submitted work. P.W. Serruys is a member of the advisory board of Abbott Vascular. M. Sabaté is a member of the advisory board of Abbott Vascular and iVascular. The other authors have no conflicts of interest to declare. The study collaborators have no conflicts of interest to declare. The Guest Editor is a consultant for Edwards Lifesciences.
To read the full content of this article, please download the PDF.